Hmo mixture for treating autoimmune diseases

An autoimmune and disease technology, applied in allergic diseases, metabolic diseases, bacteria used in food preparation, etc., can solve problems such as lack of probiotic efficacy

Pending Publication Date: 2021-01-01
GLYCOM AS
View PDF20 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, other probiotics have not produced positive results in animal models
Also, there is a lack of evidence for the efficacy of probiotics in humans

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Hmo mixture for treating autoimmune diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0094] A total of 100 male and female healthy adults were recruited to participate in the study. After the screening visit and a 1-2 week run-in period, participants were selected and randomized into ten groups of ten subjects each. Group 1 was administered a placebo product containing 2 grams of glucose. The remaining 9 groups were administered a therapeutic product containing: a) 20 g 2'-FL, b) 10 g 2'-FL, c) 5 g 2'-FL, d) 20 g LNnT, e) 10 g LNnT, f) 5 g LNnT, g ) 20 g of a 2:1 by weight mixture of 2'-FL and LNnT, h) 10 g of a 2:1 by weight mixture of 2'-FL and LNnT, and i) 5 g of a 2:1 by weight of 2' - Mixture of FL and LNnT for 4 weeks. The placebo and treatment products are in powder form in unit dose containers.

[0095] Healthy adults are eligible if they are between the ages of 18 and 60. All recruited participants were able and willing to understand and follow study procedures. Participants were excluded if: they had participated in a clinical study one month be...

Embodiment 2

[0111] The anti-inflammatory effects of HMOs were investigated in non-obese diabetic (NOD) mouse models of diabetes and Sjogren's syndrome.

[0112] The mice were divided into four groups (n=8), the control group received standard tap water, and the three treatment groups received drinking water supplemented with a mixture of 2'-FL, 2'-FL and DFL (4:1 by weight) or 6'-SL, equivalent to a human dose of approximately 10 grams per day (calculated from the metabolic rate and daily water consumption of the NOD mouse strain).

[0113] Mice were treated for 12 weeks with water changes every two weeks. From 12 weeks of age, the blood glucose levels of the mice were checked weekly. Mice with blood glucose levels above 7 mmol / l were closely monitored and were euthanized (and excluded from the study) if blood glucose levels rose to >12 mmol / l on two consecutive measurements.

[0114] After 12 weeks of treatment, mice were euthanized and the following samples were taken: serum, pancreas...

Embodiment 3

[0122] exist The effect of HMOs on the microbiota was studied in an in vitro gastrointestinal model (Prodigest). A typical reactor setup consists of four reactors in a row simulating different parts of the human gastrointestinal tract. The first two reactors adopt the filling-drawing principle, which can simulate the different steps of food intake and digestion. The peristaltic pump adds a certain amount of SHIME feed (140ml 3× / day) and pancreaticobiliary juice (60ml 3× / day), respectively Drain to stomach and small intestine compartments and empty respective reactors after specified intervals. The last two compartments are continuously stirred reactors with constant volume and pH control. The residence time and pH of the different containers were chosen to simulate in vivo conditions in different parts of the colon. The proximal colon was set at pH 5.4-5.6, dwell time = 12h, the distal colon was set at pH 6.0-6.5, dwell time = 20h. 2′-FL, LNnT or Mix (2′-FL:LNnT at a we...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a method, compounds and compositions for the secondary prevention, treatment or dietary management of symptomatic and asymptomatic non -intestinal autoimmune diseases in a non-infant human including Sjogren's syndrome and type 1 diabetes. The method, compounds and compositions for the secondary prevention, treatment or dietary management include human milk oligosaccharide(HMO), preferably mixtures of human milk oligosaccharides selected from the group of 2'-FL, LNnT, LNT, DFL, and 6'-SL.

Description

technical field [0001] The present invention relates to methods, compounds and compositions for the dietary management of symptomatic and asymptomatic parenteral autoimmune diseases in non-infant humans. Background technique [0002] Autoimmune diseases are conditions caused by an abnormal immune response against your own tissues. They are chronic and reduce quality of life. More than 80 autoimmune diseases are known to exist, including intestinal autoimmune diseases such as Crohn's disease and celiac disease, as well as rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, Grave's disease ( Grave'sdisease), Hashimoto's thyroiditis, psoriasis, Addison's disease, Sjögren's syndrome ( syndrome), vasculitis, myasthenia gravis, and type 1 diabetes mellitus and other systemic autoimmune diseases (SAD). Autoimmune diseases are the leading cause of death among young and middle-aged women in the United States. The incidence of autoimmune diseases varies, with...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/702A61K31/715A61P37/06
CPCA61K31/702A61P37/06A61K31/202A61K31/59A61K35/745A23V2002/00A61K2300/00A23V2200/324A23V2250/282A23V2400/517A23V2400/533A61K35/20A61P1/18A61P3/10A23L33/125A23L33/135A23L33/155A23L33/12A23L33/30A23V2250/71A23V2250/186A61P37/02
Inventor L·K·比格斯奈斯B·麦康奈尔K·罗修斯 克里斯滕森
Owner GLYCOM AS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap